Stephane Bancel - May 14, 2021 Form 4 Insider Report for Moderna, Inc. (MRNA)

Signature
/s/ Brian Sandstrom, as Attorney-in-Fact
Stock symbol
MRNA
Transactions as of
May 14, 2021
Transactions value $
-$1,730,254
Form type
4
Date filed
5/18/2021, 04:16 PM
Previous filing
May 14, 2021
Next filing
May 21, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MRNA Common Stock Sale -$75.5K -500 -1.51% $150.97 32.7K May 14, 2021 See Footnote F1, F2, F3
transaction MRNA Common Stock Sale -$232K -1.52K -4.67% $152.34 31.1K May 14, 2021 See Footnote F1, F3, F4
transaction MRNA Common Stock Sale -$46K -300 -0.96% $153.44 30.8K May 14, 2021 See Footnote F1, F3, F5
transaction MRNA Common Stock Sale -$91.6K -592 -1.92% $154.76 30.2K May 14, 2021 See Footnote F1, F3, F6
transaction MRNA Common Stock Sale -$168K -1.08K -3.57% $155.72 29.2K May 14, 2021 See Footnote F1, F3, F7
transaction MRNA Common Stock Sale -$295K -1.88K -6.46% $156.54 27.3K May 14, 2021 See Footnote F1, F3, F8
transaction MRNA Common Stock Sale -$281K -1.79K -6.54% $157.53 25.5K May 14, 2021 See Footnote F1, F3, F9
transaction MRNA Common Stock Sale -$268K -1.69K -6.63% $158.60 23.8K May 14, 2021 See Footnote F1, F3, F10
transaction MRNA Common Stock Sale -$64.1K -400 -1.68% $160.18 23.4K May 14, 2021 See Footnote F1, F3, F11
transaction MRNA Common Stock Sale -$192K -1.19K -5.09% $161.50 22.2K May 14, 2021 See Footnote F1, F3, F12
transaction MRNA Common Stock Sale -$16.2K -100 -0.45% $162.08 22.1K May 14, 2021 See Footnote F1, F3
holding MRNA Common Stock 6.31M May 14, 2021 Direct
holding MRNA Common Stock 7.41M May 14, 2021 See Footnote F13
holding MRNA Common Stock 9.05M May 14, 2021 See Footnote F14
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018.
F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $150.57 to $151.35. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F3 These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.
F4 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $151.80 to $152.74. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F5 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $152.94 to $153.81. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F6 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $154.11 to $155.10. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F7 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $155.12 to $156.10. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F8 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $156.14 to $157.07. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F9 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $157.18 to $158.13. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F10 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $158.23 to $159.12. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F11 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $159.75 to $160.67. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F12 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $160.98 to $161.81. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F13 These shares are owned directly by OCHA LLC ("OCHA"). The reporting person is the majority equity unit holder and the sole managing member of OCHA. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.
F14 These shares are owned directly by Boston Biotech Ventures, LLC ("Boston Biotech"). The reporting person is the majority equity unit holder and the sole managing member of Boston Biotech. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.